Details der Publikation - PLGA-Gentamicin and PLGA-Hydroxyapatite-Gentamicin Microspheres for Medical Applications

PLGA-Gentamicin and PLGA-Hydroxyapatite-Gentamicin Microspheres for Medical Applications

The purpose of this study was to create biodegradable composites using a synthetic polymer of polylactic-co-glycolic acid (PLGA), in which gentamicin or gentamicin and hydroxyapatite were included in order to achieve a local prolonged release of the drug in orthopedic disorders. The physico-chemical characterization of the biomaterial was achieved by Fourier-transform infrared spectroscopy (FT-IR), HPLC with diode array detector (DAD), and scanning electron microscopy (SEM). To determine whether the antibiotic inclusion in biomaterials alters its antibacterial activity, several studies were conducted on pathogenic bacteria present in bone infections (Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumonia, and Escherichia coli). SEM analysis showed that the surface of PLGA microspheres was modified to become slightly rough with submicron pores, which would favor the gentamicin release. Particle size distribution studied by DLS in PLGA-gentamicin and PLGA-HA-gentamicin presents small particles with diameters up to 450 nm. By HPLC-DAD we find out that the drug loading was of 13.26% (PLGA-gentamicin) and 7.28% (PLGA-HA-Gentamicin). We have also tracked the release profile of gentamicin included in the material, finding that the antibiotic release was improved by encapsulating it in delivery systems, contributing to sustained release for a long period of time (about 30 days). The biomaterials had antibacterial action on all tested microbial strains except on Pseudomonas aeruginosa..

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:56
Enthalten in:	Pharmaceutical chemistry journal - 56(2022), 5 vom: Aug., Seite 645-653

Sprache:	Englisch

Beteiligte Personen:	Turcu-Ştiolică, A. [VerfasserIn] Ciocîlteu, M. V. [VerfasserIn] Podgoreanu, P. [VerfasserIn] Neacşu, I. [VerfasserIn] Ionescu (Filip), O. L. [VerfasserIn] Nicolicescu, C. [VerfasserIn] Neamţu, J. [VerfasserIn] Amzoiu, E. [VerfasserIn] Amzoiu, E. [VerfasserIn] Manda, C. V. [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.40$jPharmazie$jPharmazeutika
Themen:	Biomaterial PLGA-gentamicin PLGA-hydroxyapatite-gentamicin Physico-chemical characterization, antibacterial activity

Anmerkungen:	© Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:	10.1007/s11094-022-02689-w

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2131896425

Internformat


LEADER	01000naa a22002652 4500
001	OLC2131896425
003	DE-627
005	20230506062312.0
007	cr uuu---uuuuu
008	230506s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11094-022-02689-w \|2 doi
035			\|a (DE-627)OLC2131896425
035			\|a (DE-He213)s11094-022-02689-w-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a PHARM \|q DE-84 \|2 fid
084			\|a 15,3 \|2 ssgn
084			\|a 44.40$jPharmazie$jPharmazeutika \|2 bkl
100	1		\|a Turcu-Ştiolică, A. \|e verfasserin \|4 aut
245	1	0	\|a PLGA-Gentamicin and PLGA-Hydroxyapatite-Gentamicin Microspheres for Medical Applications
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
520			\|a The purpose of this study was to create biodegradable composites using a synthetic polymer of polylactic-co-glycolic acid (PLGA), in which gentamicin or gentamicin and hydroxyapatite were included in order to achieve a local prolonged release of the drug in orthopedic disorders. The physico-chemical characterization of the biomaterial was achieved by Fourier-transform infrared spectroscopy (FT-IR), HPLC with diode array detector (DAD), and scanning electron microscopy (SEM). To determine whether the antibiotic inclusion in biomaterials alters its antibacterial activity, several studies were conducted on pathogenic bacteria present in bone infections (Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumonia, and Escherichia coli). SEM analysis showed that the surface of PLGA microspheres was modified to become slightly rough with submicron pores, which would favor the gentamicin release. Particle size distribution studied by DLS in PLGA-gentamicin and PLGA-HA-gentamicin presents small particles with diameters up to 450 nm. By HPLC-DAD we find out that the drug loading was of 13.26% (PLGA-gentamicin) and 7.28% (PLGA-HA-Gentamicin). We have also tracked the release profile of gentamicin included in the material, finding that the antibiotic release was improved by encapsulating it in delivery systems, contributing to sustained release for a long period of time (about 30 days). The biomaterials had antibacterial action on all tested microbial strains except on Pseudomonas aeruginosa.
650		4	\|a PLGA-gentamicin
650		4	\|a biomaterial
650		4	\|a PLGA-hydroxyapatite-gentamicin
650		4	\|a physico-chemical characterization, antibacterial activity
700	1		\|a Ciocîlteu, M. V. \|4 aut
700	1		\|a Podgoreanu, P. \|4 aut
700	1		\|a Neacşu, I. \|4 aut
700	1		\|a Ionescu (Filip), O. L. \|4 aut
700	1		\|a Nicolicescu, C. \|4 aut
700	1		\|a Neamţu, J. \|4 aut
700	1		\|a Amzoiu, E. \|4 aut
700	1		\|a Amzoiu, E. \|4 aut
700	1		\|a Manda, C. V. \|4 aut
773	0	8	\|i Enthalten in \|t Pharmaceutical chemistry journal \|d Springer US, 1967 \|g 56(2022), 5 vom: Aug., Seite 645-653 \|h Online-Ressource \|w (DE-627)325700621 \|w (DE-600)2039418-4 \|w (DE-576)121192490 \|x 1573-9031 \|7 nnns
773	1	8	\|g volume:56 \|g year:2022 \|g number:5 \|g month:08 \|g pages:645-653
856	4	0	\|u https://dx.doi.org/10.1007/s11094-022-02689-w \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a FID-PHARM
912			\|a SSG-OPC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2134
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.40$jPharmazie$jPharmazeutika \|q VZ \|0 106423304 \|0 (DE-625)106423304
951			\|a AR
952			\|d 56 \|j 2022 \|e 5 \|c 08 \|h 645-653

PLGA-Gentamicin and PLGA-Hydroxyapatite-Gentamicin Microspheres for Medical Applications

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände